![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAS |
Gene summary for FAS |
![]() |
Gene information | Species | Human | Gene symbol | FAS | Gene ID | 355 |
Gene name | Fas cell surface death receptor | |
Gene Alias | ALPS1A | |
Cytomap | 10q23.31 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P25445 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
355 | FAS | LZE4T | Human | Esophagus | ESCC | 9.35e-06 | 1.19e-01 | 0.0811 |
355 | FAS | LZE8T | Human | Esophagus | ESCC | 3.11e-08 | 2.93e-01 | 0.067 |
355 | FAS | LZE20T | Human | Esophagus | ESCC | 1.03e-05 | 3.08e-02 | 0.0662 |
355 | FAS | LZE22D1 | Human | Esophagus | HGIN | 6.30e-06 | 1.15e-01 | 0.0595 |
355 | FAS | LZE22T | Human | Esophagus | ESCC | 4.91e-02 | 2.67e-01 | 0.068 |
355 | FAS | LZE24T | Human | Esophagus | ESCC | 1.64e-11 | 2.72e-02 | 0.0596 |
355 | FAS | LZE6T | Human | Esophagus | ESCC | 3.85e-03 | 2.03e-01 | 0.0845 |
355 | FAS | P2T-E | Human | Esophagus | ESCC | 5.17e-36 | 8.88e-01 | 0.1177 |
355 | FAS | P4T-E | Human | Esophagus | ESCC | 7.55e-04 | 2.05e-02 | 0.1323 |
355 | FAS | P8T-E | Human | Esophagus | ESCC | 1.93e-19 | 2.75e-01 | 0.0889 |
355 | FAS | P9T-E | Human | Esophagus | ESCC | 3.13e-07 | 1.05e-01 | 0.1131 |
355 | FAS | P11T-E | Human | Esophagus | ESCC | 5.71e-06 | 3.92e-01 | 0.1426 |
355 | FAS | P15T-E | Human | Esophagus | ESCC | 2.41e-06 | 6.38e-02 | 0.1149 |
355 | FAS | P16T-E | Human | Esophagus | ESCC | 4.63e-02 | 2.46e-02 | 0.1153 |
355 | FAS | P21T-E | Human | Esophagus | ESCC | 3.15e-05 | 1.90e-01 | 0.1617 |
355 | FAS | P22T-E | Human | Esophagus | ESCC | 1.01e-03 | -2.44e-02 | 0.1236 |
355 | FAS | P23T-E | Human | Esophagus | ESCC | 4.67e-11 | 3.15e-01 | 0.108 |
355 | FAS | P24T-E | Human | Esophagus | ESCC | 4.87e-11 | 1.95e-01 | 0.1287 |
355 | FAS | P26T-E | Human | Esophagus | ESCC | 2.19e-07 | 9.14e-02 | 0.1276 |
355 | FAS | P27T-E | Human | Esophagus | ESCC | 9.86e-04 | 1.08e-01 | 0.1055 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
GO:003109818 | Esophagus | ESCC | stress-activated protein kinase signaling cascade | 154/8552 | 247/18723 | 8.53e-08 | 1.44e-06 | 154 |
GO:0010950111 | Esophagus | ESCC | positive regulation of endopeptidase activity | 116/8552 | 179/18723 | 1.77e-07 | 2.79e-06 | 116 |
GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:0071453110 | Esophagus | ESCC | cellular response to oxygen levels | 114/8552 | 177/18723 | 3.63e-07 | 5.06e-06 | 114 |
GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
GO:005140318 | Esophagus | ESCC | stress-activated MAPK cascade | 147/8552 | 239/18723 | 5.43e-07 | 7.18e-06 | 147 |
GO:000853512 | Esophagus | ESCC | respiratory chain complex IV assembly | 24/8552 | 26/18723 | 6.87e-07 | 8.99e-06 | 24 |
GO:003361712 | Esophagus | ESCC | mitochondrial cytochrome c oxidase assembly | 21/8552 | 22/18723 | 8.75e-07 | 1.13e-05 | 21 |
GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
GO:00009592 | Esophagus | ESCC | mitochondrial RNA metabolic process | 39/8552 | 49/18723 | 1.20e-06 | 1.49e-05 | 39 |
GO:0048872111 | Esophagus | ESCC | homeostasis of number of cells | 163/8552 | 272/18723 | 1.40e-06 | 1.69e-05 | 163 |
GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
GO:000257317 | Esophagus | ESCC | myeloid leukocyte differentiation | 128/8552 | 208/18723 | 2.75e-06 | 3.15e-05 | 128 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa0501030 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa0493230 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa0513039 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
hsa0516930 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa0516730 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa0421020 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa0517029 | Esophagus | HGIN | Human immunodeficiency virus 1 infection | 51/1383 | 212/8465 | 2.16e-03 | 1.90e-02 | 1.51e-02 | 51 |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa0516420 | Esophagus | HGIN | Influenza A | 42/1383 | 171/8465 | 3.41e-03 | 2.54e-02 | 2.02e-02 | 42 |
hsa0411510 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
hsa0516330 | Esophagus | HGIN | Human cytomegalovirus infection | 51/1383 | 225/8465 | 7.67e-03 | 4.63e-02 | 3.68e-02 | 51 |
hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa05022113 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa05010113 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa04932113 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa05130115 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
hsa05169114 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa05167114 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa04210110 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
FASLG | FAS | FASL_FAS | FASLG | Breast | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Breast | DCIS |
FASLG | FAS | FASL_FAS | FASLG | Cervix | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Cervix | CC |
FASLG | FAS | FASL_FAS | FASLG | Cervix | Healthy |
FASLG | FAS | FASL_FAS | FASLG | Cervix | Precancer |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | ADJ |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | AEH |
FASLG | FAS | FASL_FAS | FASLG | Endometrium | EEC |
FASLG | FAS | FASL_FAS | FASLG | HNSCC | OSCC |
FASLG | FAS | FASL_FAS | FASLG | THCA | ADJ |
FASLG | FAS | FASL_FAS | FASLG | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAS | SNV | Missense_Mutation | c.682N>A | p.Asp228Asn | p.D228N | P25445 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | novel | c.783G>T | p.Glu261Asp | p.E261D | P25445 | protein_coding | tolerated(0.24) | benign(0.047) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
FAS | SNV | Missense_Mutation | c.814N>C | p.Glu272Gln | p.E272Q | P25445 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD | |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
FAS | SNV | Missense_Mutation | c.628N>T | p.His210Tyr | p.H210Y | P25445 | protein_coding | tolerated(1) | benign(0.119) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
FAS | SNV | Missense_Mutation | c.793G>C | p.Asp265His | p.D265H | P25445 | protein_coding | deleterious(0.02) | benign(0.136) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FAS | SNV | Missense_Mutation | rs773565107 | c.340N>A | p.Glu114Lys | p.E114K | P25445 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
FAS | SNV | Missense_Mutation | c.542T>C | p.Leu181Pro | p.L181P | P25445 | protein_coding | tolerated(0.08) | benign(0.055) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | MPA | PROGESTERONE | 14659903 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ALL-TRANS RETINOIC ACID | 9792441 | ||
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VALPROIC ACID | 16328060 | ||
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CHOLECALCIFEROL | CHOLECALCIFEROL | 9811059 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | TENIPOSIDE | TENIPOSIDE | 9543255 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VESNARINONE | VESNARINONE | 9226479 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 11437491 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | LITHIUM | LITHIUM | 15475000 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ASPIRIN | ASPIRIN | 15200494 | |
355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | BISPECIFIC ANTIBODY | 11280736 |
Page: 1 2 3 4 |